UPMC Physician Resources

Updates from the Children’s Hospital of Pittsburgh of UPMC Division of Pediatric Hematology/Oncology

PrintUpdates from the Children’s Hospital of Pittsburgh of UPMC Division of Pediatric Hematology/Oncology:

Jake Cooper, MD, Division of Pediatric Hematology/Oncology, published a paper on portomesenteric venous thrombosis in the journal Clinical Pediatrics.

Cheryl Hillery, MD, clinical director of Hematology in the Division of Pediatric Hematology/Oncology, was invited to be part of the NIH NHLBI Clinical Trials Review Committee.

Edward Prochownik, MD, PhD, Division of Pediatric Hematology/Oncology, published two manuscripts dealing witih drug development in the journal OncoTarget. OncoTarget’s mission is to make scientific results rapidly and widely available and to foster applications of basic and clinical science to fight disease. Dr. Prochownik published 12 manuscripts in 2014-15.

Mark Vander Lugt, MD, of the Division of Blood and Marrow Transplantation and Cellular Therapies, has developed a biorepository to collect and store samples from patients with primary immunodeficiencies and malignancies and who are undergoing hematopoietic stem cell transplant. The goal is to bank samples for future research in order to better understand the complex processes underlying these diseases.

The UPMC Pituitary Center

The UPMC Pituitary Center is an innovative program that offers a comprehensive team approach to treat pituitary and skull base tumors.

A team of experts, including neurosurgeons, ophthalmologists, endocrinologists, and radiologists, are available to provide consultations and testing for patients, all within the same day, allowing for a truly integrated and convenient approach to patient care.

Contact Us
For more information on the UPMC Pituitary Center, call 412-647-3685 or visit UPMC.com/Neurosurgery.

Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy)

Dennis McNamara, MD, published “Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy)” in the Journal of the American College of Cardiology in August 2015. The outcomes report noted that certain factors, including race and both the level of left ventricular dysfunction and remodeling upon entry into the study, played a crucial role in participant recovery.

Hear more about the study results from Dr. McNamara:

Association of persistent or worsened echocardiographic dyssynchrony with unfavorable clinical outcomes in heart failure patients with narrow QRS width: a subgroup of analysis of the EchoCRT trial

John Gorcsan, MD presented “Association of persistent or worsened echocardiographic dyssynchrony with unfavorable clinical outcomes in heart failure patients with narrow QRS width: a subgroup of analysis of the EchoCRT trial” at the European Society of Cardiology 2015 Congress in London, England. He discussed how while the trial showed no benefit for cardiac resynchronization therapy (CRT) for heart failure patients, a sub-study of more than 800 patients from around the world revealed that abnormalities in mechanical activation – or dyssynchrony – were markers for more advanced disease and higher incidence of follow-up heart failure, hospitalizations, and even death. With this information, cardiologists will be able to better apply CRT to more appropriate patient populations.

Read the abstract here.

Hear more about this work from Dr. Gorcsan:

Referring PAH Patients for Lung Transplant

October 24-28, 2015
Montreal, Canada

At CHEST 2015 Patty George, MD, sat down with PAH TV to discuss some factors that determine when a patient should have a lung transplant.

Watch the interview here.

American Academy of Ophthalmology 2015 Conference

The American Academy of Ophthalmology 2015 Annual Meeting will take place November 14-17 in Las Vegas. A number of UPMC Eye Center faculty members will be presenting, including:

November 14, 2015
11:28 a.m. – 1:40 p.m. Ken Nischal, MD, FRCOphth Surgical Surprises – The Morning After
11:35 – 11:50 am Gabrielle Bonhomme, MD It Hurts When I talk and this Cough won’t go Away

November 15, 2015
12:30 – 2:00 pm Gabrielle Bonhomme, MD; Tarek Shazly, MD A Novel Compact Wireless High – Resolution Eye & Head Tracking Technique
2:00 – 4:15 pm Nils Loewen, MD, PhD Ab Interno Approach to the Schlemm Canal
3:15 – 5:30 pm Joel Schuman, MD, FACS Glaucoma Laser Therapy: Innovations & Advice from the Experts
4:30 – 5:30 pm Ken Nischal, MD, FRCOphth Surgical Caveats for Pediatric Cataract Surgery

November 16, 2015
7:00 – 8:30 am Ken Nischal, MD, FRCOphth Paradigm Shift in Neonatal Corneal Opacification Nomenclature
10:15 – 12:30 pm Joel Schuman, MD, FACS Evidence-Based Guidelines in the Management of Glaucoma
12:30 – 1:30 pm Joel Schuman, MD, FACS Using OCT in Glaucoma Management
1:00 – 2:30 pm Nils Loewen, MD, PhD Ab Interno Approach to the Schlemm Canal
2:00 – 4:15 pm Joel Schuman, MD, FACS Optical Coherence Tomography: Basics and Beyond
2:00 – 3:00 pm Deepinder Dhaliwal, MD; Alex Mammen, MD; Ladan Espandar, MD; Joseph Martel, MD; Regis Kowalski, PhD Pearls for Pragmatic Microbiology in your 21st-Century Ophthalmology Practice
2:14 – 2:22 pm Ann Shue Grand Rounds – Infected, Inflamed, Under Pressure?
3:30 – 4:45 pm Ken Nischal, MD, FRCOphth The Great Debate: Pediatric Ophthalmology

For a full list of presenters, please view the AAO program.

2016 Albert C. Muse Prize for Excellence in Ophthalmology

Nominations are now being accepted for the 2016 Albert C. Muse Prize for Excellence in Ophthalmology.

The Eye & Ear Foundation of Pittsburgh and the UPMC Eye Center invite you to submit a nomination for the 2016 Albert C. Muse Prize in Ophthalmology.

The Albert C. Muse Prize was established in 2001 by the Eye & Ear Foundation of Pittsburgh to honor world leaders in the fields of ophthalmology and otolaryngology. The Prize, which alternates annually between the two fields, carries a cash award of $5,000, and recognizes individuals who have made outstanding contributions to science and medicine in the specialties.

The 2016 Albert C. Muse Prize in Ophthalmology is open to people responsible for extraordinary advances in ophthalmology and vision science. For more information, including nomination form and submission information, visit EyeandEar.org.

The deadline for nominations is January 13, 2016.

UPCI Researcher Awarded $6.3M for Studying How Food Can Lower Cancer Risks

Thomas Kensler, PhD, Professor of Pharmacology and Chemical Biology and Co-Leader of the UPCI Cancer Epidemiology and Prevention Program, was awarded a $6.3 million Outstanding Investigator Award from the National Cancer Institute (NCI). This new, 7-year award acknowledges experienced researchers and provides them with long-term support for their exceptional work. Dr. Kensler’s research focuses on chemoprevention, or how food can be used to lower the risk of developing cancer caused by unavoidable environmental toxins.

Watch Dr. Kensler discuss his work in the video below, and read the press release here.


Current Vascular Therapies: What Has Changed and What is Still the Gold Standard

Thirteenth Annual Pittsburgh Vascular Symposium
September 10 – 12, 2015
Wyndham Grand Pittsburgh Downtown, Pittsburgh, Pa.

The Thirteenth Annual Pittsburgh Vascular Symposium will feature discussion and evaluation of the current and future standards in the treatment and care of vascular patients, including endovascular and open therapies as well as medical management. This two-day conference will also include presentations and open panels, focus on new developments in technology and surgical techniques, and highlight controversies and accepted practices in the field.

This course is sponsored and organized by the UPMC Heart and Vascular Institute, Division of Vascular Surgery and offers CME credit for physicians and other professionals.

Hear more from associate course director Steven Leers, MD.


Autophagy Inhibition as a Novel Treatment Strategy for Pancreatic Cancer

In preclinical studies, Herbert Zeh III, MD, Chief of the Division of GI Surgical Oncology, and colleagues have shown that pancreatic cancer is extremely dependent on autophagy for survival, and that drugs that block autophagy increase the sensitivity of pancreatic cancer cells to chemotherapy. Dr. Zeh’s research team is currently examining the promising clinical use of the autophagy inhibitor hydroxychloroquine, best known for its activity as an anti-malarial drug, in combination with chemotherapy for the treatment of pancreatic cancer.

Watch Dr. Zeh discuss recent advances in these clinical studies.

Page 1 of 19:1 2 3 4 »Last »
  • Make A Referral

    To refer a patient, call UPMC’s 24-hour physician referral service at 1-800-544-2500 or e-mail us.
  • Information for your Patients

    UPMC’s Clinical Services page provides information for your patients on services, conditions, and treatments.